BioTryp Therapeutics
Spin-out from the University of Cambridge developing small-molecule therapeutics that inhibit bacterial biofilm formation. Focused on preclinical discovery and medicinal chemistry to produce add-on therapies for bacterial infections, with an initial indication target of urinary tract infections (UTIs). Actively engaged in collaborative R&D, grant-funded programmes, and seed-stage fundraising.
Industries
Nr. of Employees
small (1-50)
Products
Anti-biofilm small-molecule development programme
Preclinical drug discovery programme developing small molecules that inhibit biofilm formation to be used as add-on therapies to antibiotics, with an initial focus on urinary tract infections.
Anti-biofilm small-molecule development programme
Preclinical drug discovery programme developing small molecules that inhibit biofilm formation to be used as add-on therapies to antibiotics, with an initial focus on urinary tract infections.
Services
Collaborative R&D partnerships
Partnerships to advance small-molecule anti-biofilm programmes via iterative design, synthesis and assay testing in collaborative projects.
Preclinical programme development
Activities to progress medicinal chemistry and testing toward preclinical candidate selection and regulatory readiness.
Collaborative R&D partnerships
Partnerships to advance small-molecule anti-biofilm programmes via iterative design, synthesis and assay testing in collaborative projects.
Preclinical programme development
Activities to progress medicinal chemistry and testing toward preclinical candidate selection and regulatory readiness.
Expertise Areas
- Anti-biofilm small molecule discovery
- Medicinal chemistry and lead optimisation
- In vitro biofilm assay development and testing
- Preclinical drug development planning
Key Technologies
- Small-molecule therapeutics
- Medicinal chemistry
- In vitro biofilm assays
- Synthetic chemistry